GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Recruiting

Phase 2

GATE-251GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Sponsor:

Gate Neurosciences, Inc

Code:

NCT06547489

Conditions

Major Depressive Disorder

Eligibility Criteria

Sex: All

Age: 18 - 64

Healthy Volunteers: Not accepted

Interventions

Zelquistinel

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-02. This information was provided to ClinicalTrials.gov by Gate Neurosciences, Inc on 2025-03-21.